Skip to content
Open access

α-Ketoglutarate Promotes Hepatic Steatosis by Enhancing Cidec Stability via Lactylation–Ubiquitination Crosstalk

Oct 2026 · Research · Vol 9 · 0 citations · 51 references
Medicine

Abstract

α-Ketoglutarate (AKG), a key tricarboxylic acid cycle intermediate, is widely consumed as a dietary supplement by healthy individuals for its perceived anti-aging and performance-enhancing benefits. While its antidiabetic and anti-obesity effects have been reported under pathological conditions, the safety profile and mechanisms of long-term AKG intake in healthy animals remain largely unexplored. Here, we demonstrate that long-term AKG intake via food or drinking water markedly elevates hepatic triglyceride levels and induces steatosis in healthy mice by suppressing adipose triglyceride lipase (Atgl) activity. The lipid-droplet-associated protein, cell death-inducing DNA fragmentation factor 45-like effector C (Cidec), is an inhibitor of Atgl. We find that AKG stabilizes Cidec by attenuating tripartite-motif protein 21-mediated ubiquitination. Mechanistically, AKG reduces H3K4me3 at the Pck1 promoter, activating Pck1 transcription, which promotes lactate production and subsequent Cidec lactylation. This lactylation inhibits Cidec ubiquitination, restrains Atgl activity, and ultimately drives hepatic triglyceride accumulation. Hepatocyte-specific knockdown of Cidec or Pck1 markedly ameliorates AKG-induced steatosis. Collectively, our findings reveal that long-term AKG intake enhances Cidec stability through a phosphoenolpyruvate carboxykinase 1- and tripartite-motif protein 21-mediated “lactylation–ubiquitination crosstalk”, thereby inhibiting Atgl activity and contributing to hepatic steatosis in mice. These results caution that even AKG with established health benefits may pose a risk of liver injury when used chronically in healthy mice.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.